Related Experiment Video
Updated: Dec 7, 2025
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review
Ufuk Tan Timur1, Marjolein M J Caron1, Ralph M Jeuken1
1Laboratory for Experimental Orthopedics, Department of Orthopaedic Surgery, Maastricht University Medical Centre+, 6229 HX Maastricht, The Netherlands.
Abstract:
Knee osteoarthritis (OA) is a condition mainly characterized by cartilage degradation. Currently, no effective treatment exists to slow down the progression of OA-related cartilage damage. Selective COX-2 inhibitors may, next to their pain killing properties, act chondroprotective in vivo. To determine whether the route of administration is important for the efficacy of the chondroprotective properties of selective COX-2 inhibitors, a systematic review was performed according to the PRISMA guidelines. Studies investigating OA-related cartilage damage of selective COX-2 inhibitors in vivo were included. Nine of the fourteen preclinical studies demonstrated chondroprotective effects of selective COX-2 inhibitors using systemic administration. Five clinical studies were included and, although in general non-randomized, failed to demonstrate chondroprotective actions of oral selective COX-2 inhibitors. All of the four preclinical studies using bolus intra-articular injections demonstrated chondroprotective actions, while one of the three preclinical studies using a slow release system demonstrated chondroprotective actions. Despite the limited evidence in clinical studies that have used the oral administration route, there seems to be a preclinical basis for considering selective COX-2 inhibitors as disease modifying osteoarthritis drugs when used intra-articularly. Intra-articularly injected selective COX-2 inhibitors may hold the potential to provide chondroprotective effects in vivo in clinical studies.
Insights
Selective COX-2 inhibitors show potential chondroprotective effects in osteoarthritis, particularly when administered intra-articularly. Oral administration in clinical studies did not demonstrate these benefits, suggesting route of administration is key for cartilage protection.
Area of Science:
- Orthopedics
- Pharmacology
- Biomedical Engineering
Background:
- Knee osteoarthritis (OA) involves progressive cartilage degradation, with no current treatments to halt its advancement.
- Selective cyclooxygenase-2 (COX-2) inhibitors are explored for potential chondroprotective effects beyond pain relief in OA.
- The route of administration for selective COX-2 inhibitors may influence their efficacy in managing OA-related cartilage damage.
Purpose of the Study:
- To systematically review the literature on the chondroprotective properties of selective COX-2 inhibitors in vivo.
- To evaluate the impact of administration route (systemic vs. intra-articular) on the efficacy of selective COX-2 inhibitors in OA.
- To assess the potential of selective COX-2 inhibitors as disease-modifying osteoarthritis drugs.
Main Methods:
- A systematic review was conducted following PRISMA guidelines.
- Included studies investigated the effects of selective COX-2 inhibitors on OA-related cartilage damage in preclinical and clinical settings.
- Data were analyzed based on administration route: systemic, oral, bolus intra-articular, and slow-release intra-articular injections.
Main Results:
- Nine of fourteen preclinical studies showed chondroprotective effects with systemic administration of selective COX-2 inhibitors.
- Five clinical studies using oral administration failed to demonstrate significant chondroprotective actions.
- Preclinical studies with intra-articular injections (bolus and slow-release) showed promising chondroprotective effects.
Conclusions:
- Selective COX-2 inhibitors may offer chondroprotective benefits in osteoarthritis, but efficacy appears dependent on the route of administration.
- Intra-articular administration of selective COX-2 inhibitors shows preclinical promise for disease modification in OA.
- Further clinical investigation into intra-articular selective COX-2 inhibitors is warranted to confirm their chondroprotective potential in vivo.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses